Frontline Fixed-Duration Acalabrutinib Plus Venetoclax in Rapidly Progressive _IGHV_-Mutated CLL: A Case Report
# Introduction The phase III AMPLIFY trial established fixed-duration acalabrutinib plus venetoclax as an effective, all-oral, chemotherapy-free frontline therapy for chronic lymphocytic leukemia (CLL). We report the real-world use of this regimen in a patient with rapidly progressive _IGHV_-mutate...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
THE HEALTHBOOK COMPANY LTD.
2026-05-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Acceso en liña: | https://doi.org/10.36000/HBT.OH.2026.28.208 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|